Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cns Pharmaceuticals Inc (NQ: CNSP )

1.050 +0.030 (+2.94%)
Streaming Delayed Price Updated: 10:11 AM EDT, Sep 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cns Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Study Finds Traditional Chinese Medicine May Create New Way to Treat Brain Cancer
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Potentially Pivotal Berubicin Trial
Via Investor Brand Network
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Near the Top of Equities by Percentage Gain on 4/20
Via Investor Brand Network
Mechanical Nanosurgery Could Revolutionize Brain Cancer Treatment
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Global Trial Targets Unmet Medical Need in Arresting GBM Brain Cancer
Via Investor Brand Network
CNS Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Study Finds Repeated Head Trauma Increases Brain Cancer Risk
Via Investor Brand Network
Study Explores Effects of MRI Scans During Cancer Treatment
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Its Potentially Pivotal Global GBM Trial, Reports No Exposure to SVB Issues
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls Over 100 Patients in Potentially Pivotal Berubicin Study
Via Investor Brand Network
Over 100 Patients Now Enrolled in CNS Pharmaceuticals’ (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Adds Italy to Growing Portfolio of Countries for Berubicin Study
Via Investor Brand Network
CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Via ACCESSWIRE
Broad Cancer Analysis Finds Possibility for Tumor Reduction in Nearly All Cancers
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces FY 2022 Results, Corporate Update
Via Investor Brand Network
AI Screens Brain Tumor Genes in Less Than Two Minutes
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in Upcoming Virtual Investor Event
Via Investor Brand Network
Lighting Up Malignant Tissues Could Boost Precision of Surgical Removal
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Hits Key Milestone in Global GBM Clinical Trial with the Enrollment of First Patient in Spain
Via Investor Brand Network
Normalizing Blood Vessels in Tumors Could Improve Brain Cancer Immunotherapy
Via Investor Brand Network
Research Suggests Brain Cancers Could Be Detected Via Blood Tests
Via Investor Brand Network
Topics Death
Exposures Death
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces It Has No Exposure to Silicon Valley Bank Issues
Via Investor Brand Network
Study Documents Dangers of Halting Opioid Treatments for Chronic Pain
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Potentially Pivotal Berubicin Trial
Via Investor Brand Network
Researchers Find Ways to Ease Cancer Treatment Outcome Prediction
Via Investor Brand Network
New AI Tool Helps Personalize Breast Cancer Therapy
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Research Finds Most Pediatric Oncologists Don’t Discuss Prognosis with Caregivers
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls First Patient in Spain in Key Global Trial Studying Berubicin for Treatment of GBM
Via Investor Brand Network
Study Finds Boosting White Blood Cell Counts May Improve Treatment Outcomes
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Pleased with Early Results from Global Clinical Trial
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.